Tolerability,safety and survival in patients with severe pulmonary arterial hypertension treated with intravenous epoprostenol(Veletri®):6-months,open label,observational,non-interventional study
J. Degering (Heidelberg, Germany), S. Harutyunova (Heidelberg, Germany), N. Benjamin (Heidelberg, Germany), C. Eichstaedt (Heidelberg, Germany), P. Xanthouli (Heidelberg, Germany), B. Egenlauf (Heidelberg, Germany), R. Seeger (Heidelberg, Germany), E. Grünig (Heidelberg, Germany)
Source: International Congress 2022 – Treatment of pulmonary arterial hypertension
Session: Treatment of pulmonary arterial hypertension
Session type: Thematic Poster
Number: 2677
 
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
J. Degering (Heidelberg, Germany), S. Harutyunova (Heidelberg, Germany), N. Benjamin (Heidelberg, Germany), C. Eichstaedt (Heidelberg, Germany), P. Xanthouli (Heidelberg, Germany), B. Egenlauf (Heidelberg, Germany), R. Seeger (Heidelberg, Germany), E. Grünig (Heidelberg, Germany). Tolerability,safety and survival in patients with severe pulmonary arterial hypertension treated with intravenous epoprostenol(Veletri®):6-months,open label,observational,non-interventional study. 2677
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|